These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9677174)

  • 1. Lack of pharmacokinetic interaction between nelfinavir and nevirapine.
    Skowron G; Leoung G; Kerr B; Dusek A; Anderson R; Beebe S; Grosso R
    AIDS; 1998 Jul; 12(10):1243-4. PubMed ID: 9677174
    [No Abstract]   [Full Text] [Related]  

  • 2. Nelfinavir and nevirapine interaction?
    Mulcahy F; Barry M; Merry C; Back D
    AIDS; 1998 Dec; 12(17):2361. PubMed ID: 9863887
    [No Abstract]   [Full Text] [Related]  

  • 3. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
    Skowron G
    Antivir Ther; 1998; 3 Suppl 4():61-2. PubMed ID: 10723513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.
    Taylor S; Little J; Halifax K; Drake S; Back D
    J Antimicrob Chemother; 2000 May; 45(5):716-7. PubMed ID: 10797104
    [No Abstract]   [Full Text] [Related]  

  • 5. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
    Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
    Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between recreational drugs and antiretroviral agents.
    Antoniou T; Tseng AL
    Ann Pharmacother; 2002 Oct; 36(10):1598-613. PubMed ID: 12243611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of antiretroviral drugs.
    Hoetelmans RM
    Antivir Ther; 1999; 4 Suppl 3():29-41. PubMed ID: 16021869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
    Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
    Maserati R; Villani P; Seminari E; Pan A; Lo Caputo S; Regazzi MB
    AIDS; 1999 May; 13(7):870-1. PubMed ID: 10357395
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
    Merry C; Barry MG; Mulcahy F; Ryan M; Tjia JF; Halifax KL; Breckenridge AM; Back DJ
    AIDS; 1998 Jul; 12(10):1163-7. PubMed ID: 9677165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments.
    Russo G; Paganotti GM; Soeria-Atmadja S; Haverkamp M; Ramogola-Masire D; Vullo V; Gustafsson LL
    Infect Genet Evol; 2016 Jan; 37():192-207. PubMed ID: 26602158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency.
    Izzedine H; Diquet B; Launay-Vacher V; Jouan M; Theou N; Deray G
    AIDS; 1999 Oct; 13(14):1989. PubMed ID: 10513666
    [No Abstract]   [Full Text] [Related]  

  • 14. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
    Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
    J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.
    Cohn SE; Park JG; Watts DH; Stek A; Hitti J; Clax PA; Yu S; Lertora JJ;
    Clin Pharmacol Ther; 2007 Feb; 81(2):222-7. PubMed ID: 17192768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
    Gonzalez A; Everall IP
    AIDS; 1998 Dec; 12(18):2365-7. PubMed ID: 9875573
    [No Abstract]   [Full Text] [Related]  

  • 17. [New combination medications].
    Agosto M
    Sidahora; 1997; ():43-6. PubMed ID: 11364501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A
    J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
    Boffito M; Pozniak A; Kearney BP; Higgs C; Mathias A; Zhong L; Shah J
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4386-9. PubMed ID: 16189129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Etravirine drug interactions].
    Pérez VE; Sánchez-Parra C; Serrano Villar S
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():27-31. PubMed ID: 20116625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.